Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Artigo
|
![]() |
9152 A population pharmacokinetic analysis for BIBF 1120, an angiokinase inhibitor, in patients with advanced non-small cell lung cancerStopfer, P ; Freiwald, M ; Liesenfeld, K.H ; Bruno, R ; Hodge, L ; Eschbach, C ; Reck, M ; von Pawel, J ; Kaiser, R ; Staab, AEuropean journal of cancer supplements, 2009, Vol.7 (2), p.551-551 [Periódico revisado por pares]Elsevier LtdTexto completo disponível |
2 |
Material Type: Artigo
|
![]() |
9077 Phase 2 study of pemetrexed and cisplatin plus either enzastaurin or placebo in chemonaive patients with advanced NSCLCReck, M ; Ramlau, R ; VonPawel, J ; Antonio, B. San ; Visseren-Grul, C ; Chouaki, N ; Eschbach, C ; Szczesna, A ; Vansteenkiste, JEuropean journal of cancer supplements, 2009, Vol.7 (2), p.528-528 [Periódico revisado por pares]Elsevier LtdTexto completo disponível |
3 |
Material Type: Artigo
|
![]() |
9172 Analysis of biomarkers (BMs) in the AVAiL phase III randomised study of first-line Bevacizumab (Bv) with cisplatin-gemcitabine (CG) in patients (pts) with non-small cell lung cancer (NSCLC)Leighl, N ; Reck, M ; de Haas, S ; Evers, S ; Delmar, P ; Manegold, C ; Scherer, SEuropean journal of cancer supplements, 2009, Vol.7 (2), p.558-558 [Periódico revisado por pares]Elsevier LtdTexto completo disponível |
4 |
Material Type: Artigo
|
![]() |
9021 Preliminary results of MAGE-A3 expression and baseline demographic data from MAGRIT, a large phase III trial of MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic) in adjuvant NSCLCZielinski, M ; Laskowski, U ; Bieselt, R ; Reck, M ; Strausz, J ; Perdeus, J ; Park, K ; Atanackovic, D ; Debois, M ; Debruyne, CEuropean journal of cancer supplements, 2009, Vol.7 (2), p.511-512 [Periódico revisado por pares]Elsevier LtdTexto completo disponível |
5 |
Material Type: Artigo
|
![]() |
1114 Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphismXu, C ; Reck, B ; Xue, Z ; Huang, L ; Baker, K ; Chen, M ; Mooser, V ; Cardon, L ; Spraggs, C ; Pandite, LEuropean journal of cancer supplements, 2009, Vol.7 (2), p.119-119 [Periódico revisado por pares]Elsevier LtdTexto completo disponível |
6 |
Material Type: Artigo
|
![]() |
6512 ORAL Analysis of possible relationships between tumour biomarkers and clinical benefit from erlotinib in advanced non-small cell lung cancer (NSCLC): data from the prospective MERIT studyReck, M ; Milanowski, J ; Au, S.K ; Yang, P.C ; Akimov, M ; Duymelinck, C ; Gutjahr, T ; McLoughlin, P ; Hillenbach, C ; Felip, EEuropean journal of cancer supplements, 2007, Vol.5 (4), p.360-360 [Periódico revisado por pares]Elsevier LtdTexto completo disponível |
7 |
Material Type: Artigo
|
![]() |
6568 POSTER Phase II trial of the novel epothilone ZK-EPO as second-line therapy in patients with stage IIIB or stage IV non-small-cell lung cancerGatzemeier, U ; vonPawel, J ; Eschbach, C ; Brune, A ; Wagner, A ; Giurescu, M ; Reck, MEuropean journal of cancer supplements, 2007, Vol.5 (4), p.378-378 [Periódico revisado por pares]Elsevier LtdTexto completo disponível |
8 |
Material Type: Artigo
|
![]() |
6518 ORAL Subgroup results from a randomised, double-blind, multicentre phase III study of bevacizumab in combination with cisplatingemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): study BO17704Eberhardt, W ; Reck, M ; vonPawel, J ; Zatloukal, P ; Ramlau, R ; Gorbounova, V ; Leighl, N ; Mezger, J ; Moore, N ; Manegold, CEuropean journal of cancer supplements, 2007, Vol.5 (4), p.362-362 [Periódico revisado por pares]Elsevier LtdTexto completo disponível |
9 |
Material Type: Artigo
|
![]() |
6587 POSTER A phase IB, dose-finding study of erlotinib in combination with pemetrexed in patients with advanced (stage IIIB/IV) non-small-cell lung cancer (NSCLC): a preliminary analysis of the BP18193 studyRanson, M ; Reck, M ; Anthoney, A ; Hanauske, A ; Akimov, M ; Klingelschmitt, G ; Kletzl, H ; Twelves, CEuropean journal of cancer supplements, 2007, Vol.5 (4), p.384-384 [Periódico revisado por pares]Elsevier LtdTexto completo disponível |
10 |
Material Type: Artigo
|
![]() |
6503 ORAL Efficacy and safety results from BO17704, a randomised, placebo-controlled phase III study of bevacizumab in combination with cisplatin and gemcitabine in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC)Manegold, C ; vonPawel, J ; Zatloukal, P ; Ramlau, R ; Gorbounova, V ; Hirsh, V ; Leighl, N ; Mezger, J ; Moore, N ; Reck, MEuropean journal of cancer supplements, 2007, Vol.5 (4), p.357-357 [Periódico revisado por pares]Elsevier LtdTexto completo disponível |